FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...

Related Keywords

Puerto Rico ,Singapore ,United States ,America ,American ,Justin Claeys ,Jay Bradner ,Davidp Carbone ,Laurie Fenton Ambrose ,Murdo Gordon ,Instagram ,World Most Innovative Companies ,World Health Organization ,American Cancer Society ,Ohio State University Medical Center ,Beigene Ltd ,Amgen ,Amgen Safety Net Foundation ,Exchange Commission ,Linkedin ,Kyowa Kirin Co Ltd ,Youtube ,Teneobio Inc ,Drug Administration ,Fast Company ,James Thoracic Oncology Center ,Chemocentryx Inc ,Targeting Therapy ,Major Solid ,Objective Response Rate ,Median Duration ,Median Overall Survival ,Host Webcast Investor Call ,Multichannel News Release ,Bispecifict Cell Engager ,Ohio State University Medical ,Confidence Interval ,Boxed Warning ,Important Safety Information ,Webcast Investor Call ,Global Commercial Operations ,Investor Relations Events ,Important Safety ,Release Syndrome ,Prescribing Information ,Following Day ,Fetal Toxicity ,Important Dosing ,Small Cell Lung Cancer ,Most Innovative ,Best Large ,Dow Jones Industrial ,Nasdaq Stock Market ,Horizon Therapeutics ,Thousand Oaks ,Lung Cancer Survival ,Half Life Extended ,Targeted Bispecifict Cell Engager ,Shows High Potency ,Preclinical Models ,Small Cell Lung ,Clin Cancer ,Previously Treated Small Cell Lung ,Opin Mol ,Overall Survival ,World Conference ,Lung Cancer ,Extensive Stage Small Cell Lung Cancer ,Nat Rev Clin ,Recurrent Small Cell Lung Cancer ,Tarlatamab Clinical Trial ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Fda Approval ,